Abstract
In the last two decades or so the intramuscular administration of botulinum toxin type A, and more recently type B, has become an established first line treatment of many neurological and other medical disorders. So far, the toxin has been used mainly by experienced researchers and clinicians with extensive knowledge of its mode of action and potential adverse effects. However, in the foreseeable future it is likely that this treatment will be provided by more medical practitioners and in different clinical settings, especially as the range of its clinical indications increases. Botulinum toxin, in therapeutic doses, is a remarkably safe drug with relatively few adverse effects. The commonest adverse effects are muscle weakness, fatigue, flu-like symptoms, a dry mouth, dizziness and a skin rash. Nonetheless, serious adverse events may occur, albeit rarely, and it is imperative that prescribers of this treatment are thoroughly familiar with its potential risks. The purpose of this article is to review the possible adverse effects of botulinum toxin intramuscular injections, to describe the factors that might predispose to them and to summarise the strategies for their prevention and treatment.
Keywords: Botulinum toxin., adverse events, drug safety
Current Drug Safety
Title: The Possible Adverse Effects of Intramuscular Botulinum Toxin Injections and their Management
Volume: 1 Issue: 3
Author(s): A. Magid O. Bakheit
Affiliation:
Keywords: Botulinum toxin., adverse events, drug safety
Abstract: In the last two decades or so the intramuscular administration of botulinum toxin type A, and more recently type B, has become an established first line treatment of many neurological and other medical disorders. So far, the toxin has been used mainly by experienced researchers and clinicians with extensive knowledge of its mode of action and potential adverse effects. However, in the foreseeable future it is likely that this treatment will be provided by more medical practitioners and in different clinical settings, especially as the range of its clinical indications increases. Botulinum toxin, in therapeutic doses, is a remarkably safe drug with relatively few adverse effects. The commonest adverse effects are muscle weakness, fatigue, flu-like symptoms, a dry mouth, dizziness and a skin rash. Nonetheless, serious adverse events may occur, albeit rarely, and it is imperative that prescribers of this treatment are thoroughly familiar with its potential risks. The purpose of this article is to review the possible adverse effects of botulinum toxin intramuscular injections, to describe the factors that might predispose to them and to summarise the strategies for their prevention and treatment.
Export Options
About this article
Cite this article as:
Bakheit O. A. Magid, The Possible Adverse Effects of Intramuscular Botulinum Toxin Injections and their Management, Current Drug Safety 2006; 1 (3) . https://dx.doi.org/10.2174/157488606777934431
DOI https://dx.doi.org/10.2174/157488606777934431 |
Print ISSN 1574-8863 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3911 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Stenting and Prevention of Ischemic Stroke
Current Drug Targets Use of Toll-Like Receptor 3 Agonists Against Respiratory Viral Infections
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Chromogranin A as a Calcium-Binding Precursor for a Multitude of Regulatory Peptides for the Immune, Endocrine and Metabolic Systems
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents “The Tools of the Trade” – An Overview of the Pharmacology of the Endocannabinoid System
Current Pharmaceutical Design Structure-Activity Relationship Studies on Holy Basil (Ocimum sanctum L.) Based Flavonoid Orientin and its Analogue for Cytotoxic Activity in Liver Cancer Cell Line HepG2
Combinatorial Chemistry & High Throughput Screening Novel Antibody Therapeutics Targeting Mesothelin In Solid Tumors
Clinical Cancer Drugs JAK Inhibitors: Pharmacology and Clinical Activity in Chronic Myeloprolipherative Neoplasms
Current Medicinal Chemistry Anti-Hypertensive Potential and Epigenetics of Angiotensin II type 2 Receptor (AT2R)
Current Hypertension Reviews Toxicological Effects of Dietary Biogenic Amines
Current Nutrition & Food Science Cytokines as Anti-Angiogenic Agents in Haematological Malignancies
Current Cancer Drug Targets Prognosis and Treatment of Ventricular Arrhythmias Following Myocardial Infarction
Current Cardiology Reviews The Use of Ghrelin and Ghrelin Receptor Agonists as a Treatment for Animal Models of Disease: Efficacy and Mechanism
Current Pharmaceutical Design Association Between Heart Rate Variability and Parkinson’s Disease: A Meta-analysis
Current Pharmaceutical Design Antidote Control of Aptamer Therapeutics: The Road to a Safer Class of Drug Agents
Current Pharmaceutical Biotechnology The Clinical Problems of Hypertension Treatment in Hemodialysis Patients
Current Vascular Pharmacology Molecular Regulation and Pharmacology of Pacemaker Channels
Current Pharmaceutical Design Side Effects of Clozapine and Some Other Psychoactive Drugs
Current Drug Safety Prevention of Endothelial Cell Injury by Activated Protein C: The Molecular Mechanism(s) and Therapeutic Implications
Current Vascular Pharmacology Using Mass Spectrometry-Based Peptidomics to understand the Brain and Disorders such as Parkinson’s Disease and Schizophrenia
Current Topics in Medicinal Chemistry Neuroprotective Effects of Drug-Induced Therapeutic Hypothermia in Central Nervous System Diseases
Current Drug Targets